Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Previous Stories

Dr Boreham’s Crucible: Race Oncology

Apr 09 2024

Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports

And Now For Something Different: Royalties

Apr 02 2024

The New Criterion’s Tim Boreham explains the benefits of royalties and where to access them via the ASX

Dr Boreham’s Crucible: Hydrix

Mar 26 2024

Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX

Life360 Growth Outlook Boosted By Advertising

Mar 20 2024

Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations

Capitol Health’s Higher Margin Outlook

Mar 13 2024

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control

Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked

Dicker Data Still PC

Mar 07 2024

Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook

February Small Cap Winners & Losers

Feb 29 2024

Profit season brings out the best and worst in small caps, and sometimes both at once, reports The New Criterion’s Tim Boreham

Hansen Technologies: Focus On FY26

Feb 26 2024

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say

Data#3 Guilty Of Miscommunication

Feb 19 2024

While Data3#’s earnings result confirmed its January trading update, the market was not impressed with how profit growth was achieved

Analyse The Market From A Different Angle